Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 140

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 140
---
 their employment activities, but outside the performance of their contractual duties, NLS is required to compensate the employee for the rights to their respective inventions. There can be no guarantee that NLS will be able to obtain any such inventions and the failure to obtain such ownership rights over employee inventions could have a material adverse effect on its operations and ability to effectively compete. Risks Related to its Business Operations NLS manages its business through a small number of key employees and consultants. As of June 20, 2025, NLS’s key employees and consultants include its Chief Executive Officer, Mr. Alexander Zwyer, its Chief Financial Officer, Nicole Fernandez -McGovern, and its Chief Scientific Officer, Eric Konofal. Its future growth and success depend on its ability to recruit, retain, manage and motivate its employees and key consultants. 48 The loss of the services of its Chief Executive Officer or any of its senior management or the inability to hire or retain experienced management personnel could adversely affect its ability to execute its business plan and harm its operating results. In addition, laws and regulations on executive compensation, including legislation in its home country, Switzerland, may restrict its ability to attract, motivate and retain the required level of qualified personnel. In Switzerland, legislation affecting public companies has been passed that, among other things, (i) imposes an annual binding shareholders’ “say -on-pay” vote with respect to the compensation of the members of (a) the senior management and (b) the board of directors, (ii) prohibits severance, advances, transaction premiums and similar payments to senior management and directors, and (iii) requires companies to specify various compensation -relatedmatters in their articles of association, thus requiring them to be approved by a shareholders’ vote. Because of the specialized scientific and managerial nature of its business, NLS relies heavily on its ability to attract and retain qualified scientific and technical consultants. In particular, the loss of one or more of its senior management or key consultants could be detrimental to it if NLS cannot recruit suitable replacements in a timely manner. NLS does not currently carry “key person” insurance on the lives of members of senior management. The competition for qualified personnel in the pharmaceutical industry is intense. Due to this intense competition, NLS may be unable to attract and retain qualified personnel necessary for the development of its business or to recruit suitable replacement personnel. NLS may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws.